for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

NicOx SA

NCOX.PA

Latest Trade

4.76EUR

Change

-0.14(-2.76%)

Volume

177,799

Today's Range

4.72

 - 

4.91

52 Week Range

3.79

 - 

6.39

As of on the Euronext Paris ∙ Minimum 15 minute delay

Latest Developments

Nicox Q4 2019 Net Revenue Down At 0.6 Million Euros

Jan 21 (Reuters) - NICOX SA <NCOX.PA>::NICOX FOURTH QUARTER 2019 BUSINESS UPDATE AND FINANCIAL HIGHLIGHTS.Q4 2019 NET REVENUE OF EUR 0.6 MILLION.GROUP HAD CASH AND CASH EQUIVALENTS OF EUR 28.0 MILLION AS COMPARED WITH EUR 17.4 MILLION AT SEPTEMBER 30, 2019.NCX 470 PHASE 3 CLINICAL TRIAL PREPARATION: END-OF-PHASE 2 MEETING WITH U.S. FOOD AND DRUG ADMINISTRATION (FDA) IS SCHEDULED IN Q1 2020.NET REVENUE FOR Q4 OF 2019 WAS EUR 0.6 MILLION, COMPARED TO EUR 3.3 MILLION FOR Q4 OF 2018.DECEMBER 31, 2019 CASH POSITION DOES NOT INCLUDE LAST EUR 8 MILLION DRAWN DOWN UNDER BOND FINANCING AGREEMENT WITH KREOS CAPITAL.

Nicox’s Partner Secures Additional Approvals Of VYZULTA

Jan 16 (Reuters) - Nicox SA <NCOX.PA>::NICOX’S PARTNER SECURES ADDITIONAL APPROVALS OF VYZULTA (LATANOPROSTENE BUNOD OPHTHALMIC SOLUTION), 0.024% IN HONG KONG AND ARGENTINA.NICOX RECEIVES INCREASING TIERED NET ROYALTIES OF 6% TO 12% ON GLOBAL SALES OF VYZULTA AS WELL AS UP TO $150 MILLION IN POTENTIAL FUTURE MILESTONES.

Nicox Announces Approval For Partner Bausch + Lomb's VYZULTA® In Mexico

Jan 13 (Reuters) - NICOX SA <NCOX.PA>::TODAY ANNOUNCED THAT ITS PARTNER, BAUSCH + LOMB, HAS RECEIVED APPROVAL FOR VYZULTA® (LATANOPROSTENE BUNOD OPHTHALMIC SOLUTION), 0.024% IN MEXICO.NICOX RECEIVES INCREASING TIERED NET ROYALTIES OF 6% TO 12% ON GLOBAL SALES OF VYZULTA AS WELL AS UP TO $150 MILLION IN POTENTIAL FUTURE MILESTONES.

Nicox Says NCX 4251 Meets Primary Endpoint In Phase 2 Blepharitis Trial

Dec 19 (Reuters) - Nicox SA <NCOX.PA>::NICOX'S NCX 4251 MEETS PRIMARY ENDPOINT IN PHASE 2 BLEPHARITIS TRIAL AND SHOWS PROMISING EFFICACY IN DRY EYE DISEASE.FIRST-IN-HUMAN SAFETY AND TOLERABILITY PHASE 2 CLINICAL TRIAL 'DANUBE' IN 36 PATIENTS MET PRIMARY OBJECTIVE OF SELECTING DOSE OF NCX 4251 FOR FURTHER DEVELOPMENT.NCX 4251 0.1% ONCE DAILY (QD) TREATMENT WAS SELECTED TO ADVANCE INTO LARGER PHASE 2B CLINICAL TRIAL, SUBJECT TO MEETING WITH U.S. FDA IN EARLY 2020 AND SECURING NECESSARY FINANCIAL RESOURCES.SELECTED DOSE DEMONSTRATED PROMISING EFFICACY IN REDUCING SIGNS AND SYMPTOMS OF ACUTE EXACERBATIONS OF BLEPHARITIS, AND REDUCING SIGNS AND SYMPTOMS OF DRY EYE DISEASE .

French healthcare group Nicox raises 12.5 mln euros

Nov 18 (Reuters) - Nicox SA <NCOX.PA>::REG-NICOX RAISES €12.5 MILLION TO ADVANCE NCX 470 INTO PHASE 3 IN GLAUCOMA.INITIATION OF FIRST U.S. PHASE 3 CLINICAL TRIAL FOR NCX 470 PLANNED FOR Q2 2020.INITIATION OF FIRST U.S. PHASE 3 CLINICAL TRIAL FOR NCX 470 PLANNED FOR Q2 2020.COMPANY EXPECTS TO BE FINANCED TO REACH TOP-LINE RESULTS FROM FIRST U.S. PHASE 3 CLINICAL TRIAL FOR NCX 470.INSTITUTIONAL INVESTORS PARTICIPATING IN FINANCING INCLUDE U.S.-BASED SPECIALIST HEALTHCARE INVESTORS AND LONG-TERM NICOX SHAREHOLDER HBM HEALTHCARE INVESTMENTS.NICOX GROUP HAD CASH AND CASH EQUIVALENTS OF EUR 17.6 MILLION (EXCLUDING PROCEEDS OF THIS FINANCING) AS AT OCTOBER 31, 2019.ISSUANCE OF 3,315,650 NEW ORDINARY SHARES WITH GROSS PROCEEDS OF EUR 12.5 MILLION.EXPECTS 2020 REVENUE TO INCLUDE ROYALTIES ON SALES OF VYZULTA® AND ZERVIATE(TM), FOLLOWING ZERVIATE'S PLANNED COMMERCIAL LAUNCH IN $400 MILLION U.S. OCULAR ALLERGY MARKET.EXPECTS UP TO EUR 5.5 MILLION IN MILESTONE PAYMENTS FROM PARTNER OCUMENSION THERAPEUTICS RELATED TO INITIATION OF U.S. NCX 470 PHASE 3 MONT BLANC CLINICAL TRIAL BY NICOX, AND OCUMENSION'S PLANNED NCX 470 PHASE 3 CLINICAL TRIAL IN CHINA.

Nicox Reports Positive Results Of Secondary Analyses From Phase 2 Trial Of NCX 470

Oct 22 (Reuters) - NICOX SA <NCOX.PA>::REG-NICOX REPORTS POSITIVE RESULTS OF SECONDARY ANALYSES FROM PHASE 2 TRIAL FURTHER HIGHLIGHTING POTENTIAL OF NCX 470 IN GLAUCOMA.PHASE 3 CLINICAL PROGRAM EXPECTED TO BE INITIATED IN Q2 2020 WITH 0.065% AND 0.1% DOSES, PENDING END-OF-PHASE 2 MEETING WITH U.S. FOOD AND DRUG ADMINISTRATION (FDA).NCX 470 SHOWED IMPROVED IOP LOWERING WITH EACH INCREMENTAL CONCENTRATION OF NCX 470 TESTED, SETTING STAGE FOR POTENTIALLY FURTHER IOP LOWERING AT A HIGHER DOSE.NCX 470 0.065% PRODUCED SIGNIFICANTLY SUPERIOR INTRAOCULAR PRESSURE (IOP) LOWERING COMPARED WITH LATANOPROST 0.005% IN SECONDARY ANALYSES.

Nicox Q3 Net Revenue Up At 0.5 Million Euros

Oct 16 (Reuters) - NICOX SA <NCOX.PA>::Q3 2019 NET REVENUE OF EUR 0.5 MILLION.POSITIVE TOPLINE RESULTS FROM DOLOMITES PHASE 2 CLINICAL TRIAL OF NCX 470 IN GLAUCOMA.IN Q3 VYZULTA PRESCRIPTIONS EXCEEDED 3,000 PER WEEK FOR FIRST TIME.AS OF SEPTEMBER 30, 2019, THE NICOX GROUP HAD CASH AND CASH EQUIVALENTS OF €17.4 MILLION.NICOX AMENDED ITS BOND FINANCING AGREEMENT WITH KREOS CAPITAL AND DREW DOWN EUR 4 MILLION IN ADDITIONAL DEBT..AS OF SEPTEMBER 30, 2019, THE NICOX GROUP HAD FINANCIAL DEBT OF €7.4 MILLION IN THE FORM OF A BOND FINANCING AGREEMENT WITH KREOS CAPITAL SIGNED IN JANUARY 2019..NICOX MAY DRAW DOWN A FURTHER EUR 3 MILLION OR EUR 8 MILLION ON DECEMBER 31.

Nicox Amends Bond Agreement With Kreos, Draws Down Further 4 Million Euros

Oct 10 (Reuters) - Nicox SA <NCOX.PA>::NICOX AMENDS BOND FINANCING AGREEMENT WITH KREOS AND DRAWS DOWN ADDITIONAL €4 MILLION.NICOX MAY NOW DRAW DOWN A FURTHER EUR 3 MILLION OR EUR 8 MILLION ON DECEMBER 31, 2019, SUBJECT TO NOTICE TO KREOS BY DECEMBER 16, 2019.

Nicox H1 Net Loss Lowers To EUR 0.8 Mln

Sept 17 (Reuters) - Nicox SA <NCOX.PA>::H1 2019 NET REVENUE (1)OF EUR 5.6 MILLION AND NET LOSS (2)OF EUR 0.8 MILLION.ENROLLMENT COMPLETED IN NCX 470 PHASE 2 DOLOMITESCLINICAL TRIAL IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION. TOP-LINE RESULTS ON TRACK FOR EARLY Q4 2019.H1 NET LOSS FOR THE PERIOD EUR 0.8 MILLION VERSUS LOSS OF EUR 7.7 MILLION YEAR AGO.H1 OPERATING LOSS EUR 5.3 MILLION VERSUS LOSS OF EUR 8.7 MILLION YEAR AGO.H1 LOSS BEFORE TAX EUR 4.6 MILLION VERSUS LOSS OF EUR 7.6 MILLION YEAR AGO.AS OF JUNE 30, 2019, NICOX GROUP HAD FINANCIAL DEBT OF €7.4 MILLION IN THE FORM OF BOND FINANCING AGREEMENT WITH KREOS CAPITAL SIGNED IN JANUARY 2019.TOP-LINE RESULTS OF NCX 4251 PHASE 2 CLINICAL TRIAL ON TRACK FOR Q4 2019.AS OF JUNE 30 CASH AND CASH EQUIVALENTS OF €17.3 MILLION.

Nicox Q2 Net Revenue Up At EUR 5.2 Million

July 17 (Reuters) - Nicox SA <NCOX.PA>::NICOX: SECOND QUARTER 2019 BUSINESS UPDATE AND FINANCIAL HIGHLIGHTS.ENROLLMENT COMPLETED IN NCX 470 PHASE 2 CLINICAL TRIAL IN PATIENTS WITH GLAUCOMA AND OCULAR HYPERTENSION WITH RESULTS EXPECTED IN EARLY Q4 OF THIS YEAR.Q2 2019 NET REVENUE, INCLUDING LICENSING PAYMENTS, OF EUR 5.2 MILLION.TOTAL NUMBER OF PRESCRIPTIONS FOR VYZULTA IN U.S. IN Q2 OF 2019 INCREASED BY 17% COMPARED TO Q1 2019.AS OF JUNE 30, 2019, THE NICOX GROUP HAD CASH AND CASH EQUIVALENTS OF €17.3 MILLION.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up